Video

The Pros and Cons of Limited Distribution

Adam J. Fein of Drug Channels explains the reasons drug manufacturers choose limited distribution channels.

Adam Fein of Drug Channels explains the reasons drug manufacturers choose limited distribution channels.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
Inflammation concept, inflammated human tissues 3d rendering - Image credit: picture-waterfall | stock.adobe.com
Related Content
X-ray image of kidneys with CKD -- Image credit: Crystal light | stock.adobe.com
July 2nd 2025

FDA Issues Complete Response Letter to Manufacturer of OLC, Treatment for CKD-Related Hyperphosphatemia

Gillian McGovern, Associate Editor
Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder
March 31st 2025

Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder

Luke Halpern, Assistant Editor
Cardiomyopathy (ATTR-CM) -- Image credit: Dzmitry | stock.adobe.com
July 1st 2025

Pharmacists Have a Crucial Role Helping Patients With ATTR-CM Navigate Treatment With Tafamidis

Gillian McGovern, Associate Editor Jennifer Goldman, PharmD, CDES, BC-ADM, FCCP
Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education
February 28th 2025

Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education

Luke Halpern, Assistant Editor Jill Simonian, PharmD Codi Peterson, PharmD, MS
In Control Room Doctor and Radiologist Discuss Diagnosis while Watching Procedure and Monitors Showing Brain Scans Results, In the Background Patient Undergoes MRI or CT Scan Procedure.
June 27th 2025

Chronic IVIG Therapy May Reduce Incidence of Cancer, Especially in Patients With CIDP

Luke Halpern, Assistant Editor
Creative layout of colorful pills and capsules on blue background. Minimal medical concept. Pharmaceutical, Covid-19 or Coronavirus. Flat lay, top view
June 26th 2025

Mid-Year Roundup: FDA’s Novel Retail and Specialty Drug Approvals in 2025

Luke Halpern, Assistant Editor